Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 22275397)

1.

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.

Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, Melzer N, Kakkar AK; TOPIC Investigators.

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):159-65. doi: 10.1177/1076029611433769. Epub 2012 Jan 23.

PMID:
22275397
2.

A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.

Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH.

J Bone Joint Surg Am. 2000 Jul;82-A(7):929-38.

PMID:
10901307
3.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.

4.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
5.

Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.

Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, Le Maître A, Leighl NB, Shepherd FA.

Cancer. 2009 Dec 1;115(23):5516-25. doi: 10.1002/cncr.24596.

6.
7.

Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.

Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL, O'Connell MB, Ohar JA, Young TR; Enoxaparin Clinical Trial Group.

J Bone Joint Surg Am. 2001 Jun;83-A(6):900-6.

PMID:
11407799
8.

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

Saccullo G, Malato A, Raso S, Santoro M, Zammit V, Casuccio A, Siragusa S.

Am J Hematol. 2012 Apr;87(4):388-91. doi: 10.1002/ajh.23122. Epub 2012 Feb 28.

PMID:
22374861
9.
11.

Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.

Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A.

Acta Oncol. 2014 Sep;53(9):1230-7. doi: 10.3109/0284186X.2014.934397. Epub 2014 Aug 27. Review.

PMID:
25162954
13.

Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.

Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group.

Circulation. 2004 Aug 17;110(7):874-9. Epub 2004 Aug 2.

14.

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.

Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D.

Arch Intern Med. 2002 Aug 12-26;162(15):1729-35.

PMID:
12153376
15.

Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism.

Marchena PJ, Nieto JA, Guil M, García-Bragado F, Rabuñal R, Boccalon H, Trujillo-Santos J, Monreal M; RIETE Investigators.

Thromb Haemost. 2012 Jan;107(1):37-43. doi: 10.1160/TH11-06-0423. Epub 2011 Nov 24. Erratum in: Thromb Haemost. 2012 Apr;107(4):801. multiple investigator names added.

PMID:
22116496
16.

Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia.

Aleem A, Al Diab AR, Alsaleh K, Algahtani F, Alsaeed E, Iqbal Z, El-Sherkawy MS.

Asian Pac J Cancer Prev. 2012;13(4):1311-5.

17.

Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies.

Louzada ML, Majeed H, Dao V, Wells PS.

Blood Coagul Fibrinolysis. 2011 Mar;22(2):86-91. doi: 10.1097/MBC.0b013e328341f030. Review.

PMID:
21245746
18.

An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.

Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C, Bramlage P, Riess H.

Expert Opin Pharmacother. 2010 Dec;11(18):2953-61. doi: 10.1517/14656566.2010.521498. Epub 2010 Oct 18.

PMID:
20950224
19.

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.

Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI.

Thromb Haemost. 2010 Sep;104(3):642-9. doi: 10.1160/TH10-02-0142. Epub 2010 Jun 29.

PMID:
20589317
20.

Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group.

Le Maître A, Ding K, Shepherd FA, Leighl N, Arnold A, Seymour L; NCIC Clinical Trials Group.

J Thorac Oncol. 2009 May;4(5):586-94. doi: 10.1097/JTO.0b013e31819f9a8a.

PMID:
19357539
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk